Candel Therapeutics Reveals Early Survival Data From Lung Cancer Trial
Portfolio Pulse from Vandana Singh
Candel Therapeutics Inc (NASDAQ:CADL) has revealed updated activity data from its ongoing phase 2 trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor treatment in patients with non-resectable, stage III/IV non-small cell lung cancer. Of the 40 evaluable patients, 15 have lived ≥ 12 months; of these, 10 patients have lived > 18 months. Candel expects to share topline overall survival data for Cohort 2 in the second quarter of 2024. CADL shares are down 18.24% at $0.92 on the last check Tuesday.
September 26, 2023 | 4:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Candel Therapeutics' ongoing phase 2 trial of CAN-2409 shows promising survival data, with topline data expected in Q2 2024. However, CADL shares are down 18.24% at $0.92.
The promising survival data from Candel Therapeutics' ongoing phase 2 trial of CAN-2409 could potentially boost investor confidence in the company's research and development capabilities. However, the recent drop in CADL shares indicates that the market may have reacted negatively to other factors not mentioned in the news. The expected release of topline data in Q2 2024 could potentially influence the stock's performance in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100